Cargando…
Pharmacological treatment of chronic obstructive pulmonary disease
None of the drugs currently available for chronic obstructive pulmonary disease (COPD) are able to reduce the progressive decline in lung function which is the hallmark of this disease. Smoking cessation is the only intervention that has proved effective. The current pharmacological treatment of COP...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707800/ https://www.ncbi.nlm.nih.gov/pubmed/18044097 |
_version_ | 1782169184887635968 |
---|---|
author | Montuschi, Paolo |
author_facet | Montuschi, Paolo |
author_sort | Montuschi, Paolo |
collection | PubMed |
description | None of the drugs currently available for chronic obstructive pulmonary disease (COPD) are able to reduce the progressive decline in lung function which is the hallmark of this disease. Smoking cessation is the only intervention that has proved effective. The current pharmacological treatment of COPD is symptomatic and is mainly based on bronchodilators, such as selective β(2)-adrenergic agonists (short- and long-acting), anticholinergics, theophylline, or a combination of these drugs. Glucocorticoids are not generally recommended for patients with stable mild to moderate COPD due to their lack of efficacy, side effects, and high costs. However, glucocorticoids are recommended for severe COPD and frequent exacerbations of COPD. New pharmacological strategies for COPD need to be developed because the current treatment is inadequate. |
format | Text |
id | pubmed-2707800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-27078002009-07-27 Pharmacological treatment of chronic obstructive pulmonary disease Montuschi, Paolo Int J Chron Obstruct Pulmon Dis Reviews None of the drugs currently available for chronic obstructive pulmonary disease (COPD) are able to reduce the progressive decline in lung function which is the hallmark of this disease. Smoking cessation is the only intervention that has proved effective. The current pharmacological treatment of COPD is symptomatic and is mainly based on bronchodilators, such as selective β(2)-adrenergic agonists (short- and long-acting), anticholinergics, theophylline, or a combination of these drugs. Glucocorticoids are not generally recommended for patients with stable mild to moderate COPD due to their lack of efficacy, side effects, and high costs. However, glucocorticoids are recommended for severe COPD and frequent exacerbations of COPD. New pharmacological strategies for COPD need to be developed because the current treatment is inadequate. Dove Medical Press 2006-12 2006-12 /pmc/articles/PMC2707800/ /pubmed/18044097 Text en © 2006 Dove Medical Press Limited. All rights reserved |
spellingShingle | Reviews Montuschi, Paolo Pharmacological treatment of chronic obstructive pulmonary disease |
title | Pharmacological treatment of chronic obstructive pulmonary disease |
title_full | Pharmacological treatment of chronic obstructive pulmonary disease |
title_fullStr | Pharmacological treatment of chronic obstructive pulmonary disease |
title_full_unstemmed | Pharmacological treatment of chronic obstructive pulmonary disease |
title_short | Pharmacological treatment of chronic obstructive pulmonary disease |
title_sort | pharmacological treatment of chronic obstructive pulmonary disease |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707800/ https://www.ncbi.nlm.nih.gov/pubmed/18044097 |
work_keys_str_mv | AT montuschipaolo pharmacologicaltreatmentofchronicobstructivepulmonarydisease |